Harvard Bioscience, Inc. HBIO
9.68 USD +0.42 (+4.54%)
At closeNov 11, 2026, 4:00 PM EST
9.82 +0.14 +1.45%
After hours · Nov 11, 4:00 PM ET
9.30 Day range 10.20
4.00 52-week range 10.20
- YTD
- +44.48%
- 1 year
- +58.69%
News
seekingalpha.com Harvard Bioscience, Inc. (HBIO) Q3 2026 Earnings Call Transcript Harvard Bioscience, Inc. (HBIO) Q3 2026 Earnings Call Transcript
benzinga.com Harvard Bioscience Q3 2026 Earnings Call Transcript Harvard Bioscience (NASDAQ:HBIO) reported third-quarter financial results on Tuesday. The transcript from the company’s third-quarter earnings call has been provided below.Benzinga APIs provide…
benzinga.com Harvard Bioscience Raises FY2026 Sales Guidance from $88.281M-$90.012M to $89.147M-$90.877M vs $89.794M Est Harvard Bioscience (NASDAQ:HBIO) raises FY2026 sales outlook from $88.281 million-$90.012 million to $89.147 million-$90.877 million vs $89.794 million estimate.
benzinga.com Harvard Bioscience Sees Q4 Sales $23.700M-$25.500M vs $24.500M Est Harvard Bioscience (NASDAQ:HBIO) sees Q4 sales of $23.700 million-$25.500 million vs $24.500 million analyst estimate.
globenewswire.com Harvard Bioscience Announces Third Quarter 2026 Financial Results Third Quarter 2026 Revenue Growth of 8% Year Over Year to $22.2 Million Reaffirms Full Year 2026 Revenue Guidance of 3%-5% Year Over Year Growth HOLLISTON, Mass., Nov. 10, 2026 (GLOBE NEWSWIRE) --…
globenewswire.com Harvard Bioscience to Participate in the Canaccord Genuity MedTech, Diagnostics, and Digital Health and Services Forum HOLLISTON, Mass., Nov. 04, 2026 (GLOBE NEWSWIRE) -- Harvard Bioscience, Inc. (Nasdaq: HBIO) today announced that John Duke, President and Chief Executive Officer, and Mark Frost, Chief Financial…
globenewswire.com Harvard Bioscience Schedules Third Quarter 2026 Earnings Conference Call for November 10, 2026 at 8:00 AM ET HOLLISTON, Mass., Oct. 27, 2026 (GLOBE NEWSWIRE) -- Harvard Bioscience, Inc. (Nasdaq: HBIO) will announce its financial results for the quarter ended September 30, 2026, before the market opens on…
globenewswire.com Harvard Bioscience Announces Creation of Scientific Advisory Board HOLLISTON, Mass., Oct. 06, 2026 (GLOBE NEWSWIRE) -- Harvard Bioscience, Inc. (Nasdaq: HBIO) today announced the creation of its Scientific Advisory Board (SAB) to guide the Company's ongoing…
benzinga.com Benchmark Maintains Speculative Buy on Harvard Bioscience, Raises Price Target to $7.5 Benchmark analyst Bruce D. Jackson maintains Harvard Bioscience (NASDAQ:HBIO) with a Speculative Buy and raises the price target from $6 to $7.5.
seekingalpha.com Harvard Bioscience, Inc. (HBIO) Q2 2026 Earnings Call Transcript Harvard Bioscience, Inc. (HBIO) Q2 2026 Earnings Call Transcript
benzinga.com Harvard Bioscience Sees FY2026 Sales $89.147M-$90.877M vs $88.600M Est. Harvard Bioscience (NASDAQ:HBIO) sees FY2026 sales of $89.147 million-$90.877 million vs $88.600 million analyst estimate. Raises Full Year 2026 Revenue Guidance to 3%-5% Year Over Year Growth.
benzinga.com Harvard Bioscience Sees Q3 Sales $21.000M-$22.600M vs $21.850M Est Harvard Bioscience (NASDAQ:HBIO) sees Q3 sales of $21.000 million-$22.600 million vs $21.850 million analyst estimate.- benzinga.com Harvard Bioscience Q2 Adj. EPS $(0.14) Beats $(0.21) Estimate, Sales $22.727M Beat $21.450M Estimate Harvard Bioscience (NASDAQ:HBIO) reported quarterly losses of $(0.14) per share which beat the analyst consensus estimate of $(0.21) by 33.33 percent. This is a 40 percent decrease over losses of…
globenewswire.com Harvard Bioscience Schedules Second Quarter 2026 Earnings Conference Call for August 11, 2026 at 8:00 AM ET HOLLISTON, Mass. , July 28, 2026 (GLOBE NEWSWIRE) -- Harvard Bioscience, Inc. (Nasdaq: HBIO) will announce its financial results for the quarter ended June 30, 2026, before the market opens on August…
benzinga.com Lensar Appoints Michael A. Rossi As Interim CFO Effective May 29, 2026 On May 25, 2026, the Board of Directors (the "Board") of LENSAR, Inc. (the "Company") appointed Michael A. Rossi to serve as the Company's Interim Chief Financial Officer and principal financial…
seekingalpha.com Harvard Bioscience, Inc. (HBIO) Q1 2026 Earnings Call Transcript Harvard Bioscience, Inc. (HBIO) Q1 2026 Earnings Call Transcript
benzinga.com Harvard Bioscience Q1 2026 Earnings Call Transcript 
benzinga.com Harvard Bioscience Sees Q2 Sales $20.500M-$22.500M vs $21.900M Est Harvard Bioscience (NASDAQ:HBIO) sees Q2 sales of $20.500 million-$22.500 million vs $21.900 million analyst estimate.
benzinga.com Harvard Bioscience Q1 Adj. EPS $(0.33) Beats $(0.62) Estimate, Sales $20.755M Miss $21.200M Estimate Harvard Bioscience (NASDAQ:HBIO) reported quarterly losses of $(0.33) per share which beat the analyst consensus estimate of $(0.62) by 46.77 percent. This is a 230 percent decrease over losses of…
globenewswire.com Harvard Bioscience Announces First Quarter 2026 Financial Results First Quarter 2026 Revenues of $20.8M and Gross Margin of 59% Consolidation of Manufacturing Operations Progressing on Schedule Reaffirms Full Year 2026 Financial Guidance HOLLISTON, Mass., May 12,…
benzinga.com Earnings Scheduled For May 12, 2026 
globenewswire.com Harvard Bioscience to Participate in Upcoming Investor Conferences HOLLISTON, Mass., May 07, 2026 (GLOBE NEWSWIRE) -- Harvard Bioscience, Inc. (Nasdaq: HBIO) today announced Chief Executive Officer, John Duke and Chief Financial Officer, Mark Frost's participation…
globenewswire.com Harvard Bioscience Schedules First Quarter 2026 Earnings Conference Call for May 12, 2026 at 8:00 AM ET HOLLISTON, Mass., April 28, 2026 (GLOBE NEWSWIRE) -- Harvard Bioscience, Inc. (Nasdaq: HBIO) will announce its financial results for the quarter ended March 31, 2026, before the market opens on May…- benzinga.com 12 Health Care Stocks Moving In Friday's Pre-Market Session
benzinga.com 12 Health Care Stocks Moving In Friday's Intraday Session 
benzinga.com Benchmark Maintains Speculative Buy on Harvard Bioscience, Raises Price Target to $6 Benchmark analyst Bruce D. Jackson maintains Harvard Bioscience (NASDAQ:HBIO) with a Speculative Buy and raises the price target from $0.6 to $6.
defenseworld.net Harvard Bioscience Q4 Earnings Call Highlights Harvard Bioscience (NASDAQ: HBIO) executives highlighted a year of "foundation building" and cost and balance sheet actions while outlining expectations for a return to growth in 2026 during the…- benzinga.com Benchmark Maintains Speculative Buy on Harvard Bioscience, Lowers Price Target to $0.6 Benchmark analyst Bruce D. Jackson maintains Harvard Bioscience (NASDAQ:HBIO) with a Speculative Buy and lowers the price target from $2 to $0.6.
seekingalpha.com Harvard Bioscience, Inc. (HBIO) Q4 2025 Earnings Call Transcript Harvard Bioscience, Inc. (HBIO) Q4 2025 Earnings Call Transcript
benzinga.com Harvard Bioscience Sees Q1 Sales $20.000M-$22.000M vs $21.250M Est Harvard Bioscience (NASDAQ:HBIO) sees Q1 sales of $20.000 million-$22.000 million vs $21.250 million analyst estimate.- benzinga.com Harvard Bioscience Q4 Sales $23.735M Beat $23.100M Estimate Harvard Bioscience (NASDAQ:HBIO) reported quarterly sales of $23.735 million which beat the analyst consensus estimate of $23.100 million by 2.75 percent. This is a 3.34 percent decrease over sales…
globenewswire.com Harvard Bioscience Announces Fourth Quarter and Full-Year 2025 Financial Results Fourth Quarter 2025 Revenues of $23.7M and Gross Margin of 59.7% Full Year 2025 Revenues of $86.6M and Gross Margin of 57.7% Interim CFO Mark Frost Appointed CFO on Permanent Basis Introduces Full…- benzinga.com Earnings Scheduled For March 12, 2026
- benzinga.com 12 Health Care Stocks Moving In Monday's After-Market Session
- benzinga.com 12 Health Care Stocks Moving In Friday's After-Market Session
- benzinga.com Harvard Bioscience Board Approves 1-For-10 Reverse Stock Split, Effective March 13 Harvard Bioscience's common stock is expected to begin trading on a post-split adjusted basis on March 16, 2026 HOLLISTON, Mass., March 06, 2026 (GLOBE NEWSWIRE) -- Harvard Bioscience, Inc.…
globenewswire.com Harvard Bioscience Announces Reverse Stock Split Harvard Bioscience's common stock is expected to begin trading on a post-split adjusted basis on March 16, 2026 HOLLISTON, Mass., March 06, 2026 (GLOBE NEWSWIRE) -- Harvard Bioscience, Inc. (Nasdaq:…
defenseworld.net Harvard Bioscience (NASDAQ:HBIO) Share Price Passes Above Two Hundred Day Moving Average – Here’s What Happened Harvard Bioscience, Inc. (NASDAQ: HBIO - Get Free Report)'s stock price passed above its two hundred day moving average during trading on Tuesday. The stock has a two hundred day moving average of…
globenewswire.com Harvard Bioscience to Participate in KeyBanc's Virtual Healthcare Forum HOLLISTON, Mass., March 03, 2026 (GLOBE NEWSWIRE) -- Harvard Bioscience, Inc. (Nasdaq: HBIO) today announced that John Duke, President and Chief Executive Officer, and Mark Frost, Interim Chief…
globenewswire.com Harvard Bioscience Schedules Fourth Quarter 2025 Earnings Conference Call for March 12, 2026 at 8:00 AM ET HOLLISTON, Mass., Feb. 26, 2026 (GLOBE NEWSWIRE) -- Harvard Bioscience, Inc. (Nasdaq: HBIO) will announce its financial results for the quarter ended December 31, 2025, before the market opens on…
defenseworld.net Harvard Bioscience (NASDAQ:HBIO) Stock Crosses Below 200 Day Moving Average – Time to Sell? Shares of Harvard Bioscience, Inc. (NASDAQ: HBIO - Get Free Report) crossed below its 200-day moving average during trading on Monday. The stock has a 200-day moving average of $0.56 and traded as…- benzinga.com Harvard Bioscience Reports Q4 Preliminary Revenue Of $23.7M Harvard Bioscience, Inc. (Nasdaq: HBIO) (the "Company" or "Harvard Bioscience"), a global leader in life science research tools, today announced preliminary financial results for the fourth quarter…
benzinga.com Harvard Bioscience Trims Footprint To Run Leaner, Faster, And Cheaper Harvard Bioscience restructures production, closing MA plant, shifting output to US and abroad. Savings expected, costs until 2027.- benzinga.com Harvard Bioscience Strikes Agreement With BroadOak Capital Partners To Offer $40M Credit Facility Of Three Term Loans Harvard Bioscience, Inc. (Nasdaq: HBIO) (the "Company" or "Harvard Bioscience"), today announced it entered into an agreement with BroadOak Capital Partners (collectively, "BroadOak"), a…
- benzinga.com Harvard Bioscience Sees Q4 Sales $22.500M-$24.500M vs $23.100M Est Harvard Bioscience (NASDAQ:HBIO) sees Q4 sales of $22.500 million-$24.500 million vs $23.100 million analyst estimate.
- benzinga.com Harvard Bioscience Q3 Sales $20.591M Beat $20.000M Estimate Harvard Bioscience (NASDAQ:HBIO) reported quarterly sales of $20.591 million which beat the analyst consensus estimate of $20.000 million by 2.96 percent. This is a 6.28 percent decrease over sales…
benzinga.com Earnings Scheduled For November 6, 2025 - benzinga.com 12 Health Care Stocks Moving In Thursday's After-Market Session
- benzinga.com 12 Health Care Stocks Moving In Thursday's Intraday Session
- benzinga.com 12 Health Care Stocks Moving In Thursday's Pre-Market Session